Lansoprazole sulfide:Exports & Compliance White Paper 2026

I. Executive Summary

Lansoprazole sulfide, CAS 103577-40-8, is the benzimidazole thioether 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]-1H-benzimidazole, the immediate precursor from which the proton pump inhibitor lansoprazole is obtained by chemoselective oxidation to the sulfoxide. It is a pharmaceutical synthesis intermediate, not an active pharmaceutical ingredient, not a finished medicine and not a consumer product, and it is supplied business to business to licensed API manufacturers, their contract development and manufacturing partners and qualified distributors under quality agreements. This paper is written from the contract manufacturing and custom synthesis standpoint and contains no dosage, administration or therapeutic guidance of any kind.

Technical value concentrates in impurity control. The intermediate must be released on assay, on individually limited related substances including the sulfoxide, which is lansoprazole itself, the sulfone from over-oxidation, the starting chloromethyl pyridine and 2-mercaptobenzimidazole, on residual solvents, on elemental impurities and on water content, all against validated methods. Because the molecule carries a thioether, it oxidises on storage, so stability behaviour and inert packaging are part of the specification rather than afterthoughts. Regulatory value then depends on where the material sits in a customer's registered synthesis: ICH Q7 and ICH Q11 define when a compound becomes an API starting material requiring GMP, and a supplier that offers clear non-GMP and GMP tiers with supporting impurity, solvent and metal data is far easier to qualify than one that quotes only assay.

Commercially, demand is derived and unforgiving. Volumes follow generic lansoprazole and dexlansoprazole production, which are mature, high-volume, tender- and procurement-driven markets where price erosion upstream is transmitted directly to the intermediate; in China, volume-based procurement of generic medicines amplifies that pressure. Supply is concentrated among Chinese and Indian producers of benzimidazole and fluorinated pyridine building blocks, with European and Japanese capacity largely captive or specialised. The sections below cover route chemistry, impurity and stability behaviour, the regulatory file that supports a customer's dossier, packaging and transit, and a supplier strategy built on GMP tiering and technical depth.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

This is an intermediate, so what matters is not pharmacology but the reactivity of the sulfur atom. The thioether is the handle through which lansoprazole is made: controlled oxidation converts the sulfide to the sulfoxide, which is the active substance, while further oxidation gives the sulfone, which is an impurity that must be held at very low levels. The same susceptibility explains why the intermediate is oxygen- and light-sensitive in storage and why oxidation control is the central process hazard for everyone handling it.

• Chemoselective Oxidation to Sulfoxide Without Over-Oxidation: The sulfide-to-sulfoxide step must stop precisely at one oxygen, since the sulfone is difficult to purge once formed and is limited tightly in the finished API, so reagent selection, stoichiometry, addition rate, temperature and quench are the controlling parameters rather than simply the oxidant employed.
• Thioether Sensitivity to Oxygen, Light and Trace Metals: The sulfur centre oxidises under air and light, with trace metal residues accelerating the reaction, so inert headspace, opaque or lined containers, low-metal process equipment and a defined retest period are what keep a lot at specification between release and use.

2.2 Synthesis and Manufacturing Technologies

The convergent route couples two fragments. One is the substituted pyridine bearing the trifluoroethoxy group and a chloromethyl substituent in the 2 position; the other is 2-mercaptobenzimidazole. Coupling proceeds by nucleophilic substitution: the thiol is converted to its thiolate with an appropriate base and displaces chloride from the chloromethyl group to give the thioether. The reaction is ordinary in principle and demanding in practice, because the chloromethyl pyridine is a reactive alkylating species that must be fully consumed and purged, and because the product oxidises readily once formed.

• Thiolate Alkylation and Impurity Fate Control: Base, solvent and addition profile are selected to drive clean carbon-sulfur bond formation while hydrolysing or purging residual chloromethyl pyridine, with workup designed so that unreacted thiol, inorganic salts and hydrolysis products separate into the aqueous phase instead of carrying into the crystallised intermediate.
• Crystallisation, Solid-Form Control and Analytical Release: Final purification is by controlled crystallisation, with solid-form and particle size managed because filtration, drying and flow behaviour affect residual solvent and oxidation rate, and release testing covers related substances by high performance liquid chromatography, residual solvents, elemental impurities, water and appearance.

2.3 Core Application Matrix

• Lansoprazole API Manufacture: The primary outlet: licensed API manufacturers and their contract partners oxidise the thioether to lansoprazole sulfoxide, so the intermediate's sulfone, sulfoxide and starting-material profile directly shapes the impurity burden and purification yield of the registered step.
• Related Benzimidazole Proton Pump Inhibitor Programs: The same thioether pyridine scaffold supports development and generic programmes on dexlansoprazole and structurally related benzimidazole compounds, where custom synthesis, route scouting and analogue supply are contracted on a research and development basis.
• Impurity Reference Standards and Analytical Method Work: Purified sulfoxide, sulfone and starting-material fractions serve as reference and impurity standards for method development, validation and specification setting, supplied as research and analytical material and not for any human use.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Three forces set the tone. Demand is derived entirely from generic proton pump inhibitor production: lansoprazole and dexlansoprazole are mature, high-volume molecules, and because finished generic prices fall under tender, procurement and volume-based procurement pressure, that pressure is passed back to intermediate suppliers with unusual speed. Supply has consolidated into fluorine-chemistry and benzimidazole clusters able to handle trifluoroethoxy pyridine chemistry, so new entrants face both capital and process safety barriers. Documentation expectations have also risen: impurity fate-and-purge studies, mutagenic impurity risk assessment under ICH M7 and nitrosamine risk assessments requested under EMA and FDA guidance are now routine parts of a technical package rather than exceptional requests.

3.2 Capacity Distribution and Export Flows

Capacity sits where fluorine chemistry and heterocyclic synthesis meet. China holds the largest intermediate base, with plants in Zhejiang, Jiangsu, Shandong and Hubei producing both the trifluoroethoxy pyridine fragment and the coupled thioether, often inside integrated fluorochemical parks, and exporting both merchant and captive volumes. India converts imported and domestic intermediate into lansoprazole API for domestic formulation and for regulated export, with API and formulation clusters in Hyderabad, Visakhapatnam, Gujarat and Maharashtra. Japan and Western Europe retain originator-linked and high-compliance capacity, much of it captive or specialised, supplying registered chains and reference material. Trade therefore typically runs Chinese intermediate to Indian and Chinese API plants, and from there to finished dose manufacturers worldwide.

3.3 Market Bifurcation and Pricing Dynamics

Pricing is best understood as the API price less the oxidation step, which makes it structurally thin and highly sensitive to finished generic tenders. Raw material drivers include the trifluoroethanol and pyridine or lutidine-based fragments behind the chloromethyl pyridine, 2-mercaptobenzimidazole, solvents and bases, and, for GMP campaigns, the cost of dedicated equipment, validation and analytical release. The GMP tier carries a clear premium over non-GMP material because it requires qualified starting materials, documented impurity fate-and-purge, cleaning validation and change control, while research-grade lots and reference-standard work are priced per project rather than per kilogram. Buyers should normalise offers to assay, individual impurity limits, residual solvent limits, elemental impurity data and retest period, since a cheaper lot without sulfone control or stability data usually costs more downstream in purification losses.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

The controlling question is where this compound sits in each customer's registered synthesis, because that determines whether GMP applies. ICH Q11 and ICH Q7 require manufacturers to justify API starting materials and to apply GMP from that point forward, and different filings place the boundary in different places. A supplier therefore cannot sell a single grade into every chain: research and development customers want RUO material with good characterisation, while commercial filings need GMP-manufactured intermediate with a supporting dossier, impurity and solvent data, and a commitment to change control.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• EU GMP for APIs, written confirmation and ASMF or CEP support: Where the intermediate is manufactured as part of a GMP chain it must comply with EU GMP Part II, equivalent to ICH Q7, with starting-material justification per ICH Q11, impurity control per ICH Q3A, written confirmation of GMP equivalence for imported active substances under the anti-falsified medicines rules, and dossier support through an active substance master file or a certificate of suitability from the European Directorate for the Quality of Medicines.
• PFAS screening: the perfluorinated methyl group: The molecule carries a trifluoroethoxy group containing a fully fluorinated methyl carbon, which brings it within the broad PFAS definition used by the Organisation for Economic Co-operation and Development and by ECHA, so suppliers should proactively screen the current universal PFAS restriction proposal, national inventories and any sector-specific derogations, since the treatment of active substances and their synthetic intermediates is instrument-specific and still evolving rather than settled.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA status, EPA PFAS reporting and FDA dossier support: Importers should confirm the TSCA inventory position of the exact substance rather than inferring it from a family listing, assess obligations under the EPA PFAS reporting rule issued under TSCA section 8(a)(7) at 40 CFR part 705 including its exemptions, and, for regulated supply, support the finished application with a drug master file and CGMP manufacture aligned to ICH Q7.
• Impurity expectations: Q3C, Q3D, M7 and nitrosamines: Customers expect residual solvent control per ICH Q3C, elemental impurity assessment per ICH Q3D, and a mutagenic impurity risk assessment per ICH M7 that controls the alkylating chloromethyl pyridine to the threshold of toxicological concern with a validated trace method, together with nitrosamine risk documentation consistent with EMA and FDA expectations for the finished medicine.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Environmental and social attention on this intermediate is dominated by fluorine. The trifluoroethoxy group places the molecule inside the corporate and regulatory PFAS debate even though it is a synthetic intermediate rather than a fluoropolymer or surfactant, and customers running PFAS phase-out programmes will ask for declarations and screening data. Beyond fluorine, the ordinary burdens of heterocyclic synthesis apply: solvent use and recovery, nitrogen- and sulfur-bearing aqueous effluent, and the energy cost of distillations and drying.

5.1 Carbon Footprint and Circular Economy

The footprint is concentrated in the fluorinated building block and in the solvent cycle. Production of trifluoroethanol and related fluorinated fragments is energy intensive and carries process-related emissions that dwarf the coupling step itself, so a declared product carbon footprint that covers only the final site is misleading. Recovery and distillation of alcoholic and dipolar aprotic solvents, vacuum drying and, where used, cryogenic or high-temperature steps make up most of the remainder, and halogenated and nitrogen-bearing effluent treatment adds a smaller but compliance-relevant block. Buyers should ask for an ISO 14067 figure with a stated system boundary and should expect the fluorinated fragment to dominate it.

5.2 Sustainable Sourcing and Traceability

Traceability requirements differ from a commodity intermediate because of the fluorine and the regulated end use. Suppliers should document the origin and specification of the trifluoroethanol-derived fragment and of 2-mercaptobenzimidazole, hold REACH and TSCA identity statements matching the substance actually shipped, and declare fluorine content and PFAS screening position so customer compliance systems can classify the material. GMP campaigns additionally require qualified starting materials, cleaning validation, batch genealogy, retention samples and data integrity across the chromatographic methods, with ISO 9001, ISO 14001 and ISO 45001 as baseline management system evidence.

VI. Supply Chain Resilience and Export Logistics

The product is a crystalline solid that is chemically sensitive rather than hazardous in transport. Oxygen, light and elevated temperature push the thioether toward sulfoxide and sulfone, which is the same degradation route the customer must suppress during oxidation, so packaging and transit are specified to keep the lot chemically unchanged rather than merely intact. Documentation, including batch identity and any regulatory letter references, travels with the goods and is inspected as often as the material itself.

6.1 Packaging Standards and Moisture/Contamination Control

• Inert Headspace and Oxygen Barrier: The solid is packed in polyethylene liners inside fibre drums, often with an aluminium barrier bag and desiccant, with the headspace displaced by nitrogen before sealing, because residual oxygen drives slow conversion to sulfoxide and sulfone during storage and transit.
• Light Protection, Cool Storage and Retest Discipline: Opaque or foil-lined containers and cool, dry storage with a defined retest period protect against photochemical and thermal oxidation, and lots that approach the retest date should be re-assayed for related substances rather than released on appearance.

6.2 Dangerous Goods Identification and Transit Protocols

The intermediate is generally shipped as non-regulated cargo by sea, air and road at ambient temperature, with any hazard classification confirmed against the current safety data sheet rather than assumed, and with temperature loggers supplied for air freight and for hot-season routes because sustained heat accelerates oxidation. Bulk consignments should not be decanted from their lined containers, and samples taken at destination should be drawn under inert gas where the lot will be held before use. On the documentation side, the invoice, certificate of analysis and batch record reference must carry the same batch number and product identity, and letters of authorisation or dossier references should be verified in advance, because a mismatch discovered at goods-in or at a customs inspection is slow and expensive to correct.

VII. Enterprise Global Expansion Strategy Guide

This is a qualification-led, tender-exposed intermediate business. The priorities below reflect how API manufacturers and their contract partners actually select a sulfide supplier.

1. Offer Clear GMP and Non-GMP Tiers With a Filing-Ready Package: Define where your material sits relative to the customer's API starting material, quote research-use and GMP grades separately, and supply impurity profiles, residual solvent data, elemental impurity assessment, M7 documentation and change-control commitments so the customer can file or re-file without a remediation project.
2. Differentiate on Oxidation and Impurity Science: Invest in sulfone control, validated trace methods for the alkylating chloromethyl fragment, fate-and-purge studies and real stability data under inert headspace, because the supplier who can prove impurity control wins the yield argument that tenders cannot decide.
3. Link Supply to Downstream API Demand and Dual-Source Inputs: Coordinate forecasts with lansoprazole and dexlansoprazole API customers, qualify two sources for the trifluoroethoxy pyridine fragment and 2-mercaptobenzimidazole, and hold validated safety stock so tender-driven demand spikes do not become shortages.

VIII. Conclusion

Lansoprazole sulfide is a narrow, technically demanding intermediate whose commercial logic is impurity economics. Its value is set by how cleanly the thioether can be made and kept, how convincingly the alkylating fragment is purged, and how well the supplier's documentation fits the customer's filing and the evolving PFAS agenda. Suppliers who quote assay alone compete on price in a market where price is already under tender pressure; suppliers who control sulfone, prove M7 compliance and support the dossier compete on qualification, which is far harder to displace.

For buyers, the discipline is to specify the intermediate as the registered route requires, to require individual impurity and solvent limits with named methods, to confirm retest and inert packaging, and to keep the material inside licensed pharmaceutical supply chains. To state the boundary once more: this is a synthesis intermediate and research material, not a finished medicine, and nothing in this paper constitutes dosage, administration or therapeutic guidance of any kind.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Lansoprazole sulfide Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Lansoprazole sulfide supply chain:

• China: integrated fluorine chemistry and intermediate base: Zhejiang, Jiangsu, Shandong and Hubei producers make both the trifluoroethoxy pyridine fragment and the coupled thioether, frequently inside integrated fluorochemical parks, supplying merchant buyers and captive API conversion at competitive cost.
• India: API conversion and regulated-market export: API and formulation clusters in Hyderabad, Visakhapatnam, Gujarat and Maharashtra convert imported and domestic intermediate into lansoprazole API for domestic use and regulated export, and are the main demand interface for intermediate suppliers.
• Japan and the European Union: compliance-intensive, often captive: Originator-linked and specialised capacity in Japan and Western Europe operates under the strictest GMP and impurity expectations, much of it captive to registered chains, and sets the analytical and documentation standards exporters must satisfy.